Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 91-97

  Kawamura, I ^a   Morishita, R ^b   Tomita, N ^b   Lacey, E ^a   Aketa, M ^a   Tsujimoto, S ^a   Manda, T ^a   Tomoi, M ^a   Kida, I ^b   Higaki, J ^b   Kaneda, Y ^c   Shimomura, K ^a   Ogihara, T ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cachexia; Colon26; Cytokine; Decoy; Gene therapy; HVJ liposome method

Indexed keywords

CYTOKINE; INTERLEUKIN 6; OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BODY WEIGHT; CACHEXIA; CELL CYCLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; EPIDIDYMIS FAT; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; MALE; MOUSE; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; BINDING SITES; CACHEXIA; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; CYTOKINES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-6; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; OLIGONUCLEOTIDES; RESPIROVIRUS; RNA, MESSENGER;

ANIMALIA;

EID: 6544264325     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300819     Document Type: Article

References (38)

1. DeWys WD et al. Prognostic effect of weight loss proir to chemotherapy in cancer patients. Am J Med 1980; 69: 491-497.
2. Curtis EB, Krech R, Walsh TDJ. Common symptoms in patients with advanced cancer. Palliat Care 1991; 7: 25-29.
3. Kern KA, Norton JA. Cancer cachexia. J Parenter Enter Nutr 1988; 12: 286-298.
4. Soda K, Kawakami M. Cancer cachexia: pathogenesis and possible role of cytokines. Ann Cancer Res Ther 1994; 3: 73-81.
5. Espat NJ, Copeland EM, Moldawer LL. Tumour necrosis factor and cachexia: a current perspective. Surg Oncol 1994; 3: 255-262.
6. Costelli P et al. Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92: 2783-2789.
7. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684.
8. Matthys P et al. Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 1991; 49: 77-82.
9. Darling G et al. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 1990; 50: 4008-4013.
10. Greenberg AS et al. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52: 4113-4116.
11. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250: 997-1000.
12. Sullenger BA, Gallardo HF, Ungers GE, Giboa E. Overexpression of TAR sequence renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601-608.
13. Yamada T et al. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. J Clin Invest 1995; 96: 1230-1237.
14. Morishita R et al. A novel molecular strategy using cis-element 'decoy' of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
15. Morishita R et al. Role of transcriptional cis-elements, angiotensinogen gene-activating element, of angiotensinogen gene in blood pressure regulation. Hypertension 1996; 27: 502-507.
16. Lenardo MJ, Baltimore D. NF-kappa B: a pleitropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227-229.
17. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10: 2327-2334.
18. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994; 10: 405-455.
19. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12: 141-179.
20. Neish AS et al. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 1992; 176: 1583-1593.
21. Brennan DC, Jevnikar AM, Takei F, Reubin-Kelley VE. Mesangial cell accessory functions: mediation by intracellular adhesion molecule-1. Kidney Int 1990; 38: 1039-1046.
22. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996; 85: 457-459.
23. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1994; 71: 1286-1290.
24. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996; 381: 713-716.
25. Pearson BE, Nasheuer HP, Wang TSF. Human DNA polymerase α gene: sequences controlling expression in cycling and serum-stimulated cells. Mol Cell Biol 1991; 11: 2081-2095.
26. Dalton S. Cell cycle regulation of the human cdc2 gene. EMBO J 1992; 11: 1797-1804.
27. Kim YK, Lee AS. Identification of a 70-base-pair cell cycle regulatory unit within the promoter of the human thymidine kinase gene and its interaction with cellular factors. Mol Cell Biol 1991; 11: 2296-2302.
28. Hiebert SW, Lipp M, Nevins JR. E1A-dependent trans-activation of the human myc promoter is mediated by the E2F factor. Proc Natl Acad Sci USA 1989; 86: 3594-3598.
29. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424-429.
30. Tanaka Y et al. Experimental cancer cachexia induced by transplantable colon26 adenocarcinoma in mice. Cancer Res 1990; 50: 2290-2295.
31. Strassmann G, Masui Y, Chizzonite R, Fong MJ. Mechanisms of experimental cancer cachexia: local involvement of IL-1 in colon-26 tumor. Immunology 1993; 150: 2341-2345.
32. Zhang Y, Lin JX, Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a κB-like sequence. Mol Cell Biol 1990; 10: 3818-3823.
33. Soda K, Kawakami M, Kashii A, Miyata M. Manifestation of cancer cachexia induced by colon26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 1995; 62: 332-336.
34. Yasumoto K et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995; 55: 921-927.
35. Tomita N et al. In vivo gene therapy of anti-Thy 1 nephritis using E2F decoy oligonucleotides. J Am Soc Nephrol 1995; 6: 887 (Abstr.).
36. Morishita R et al. In vivo transfection of ris-element 'decoy' against NpκB binding site prevented myocardial infarction as gene therapy. Nature Med 1997; 3: 894-899.
37. Morishita R et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-1464.
38. Morishita R et al. Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. Gene 1994; 149: 13-19.